Physician profile
Joseph Ratchford
NPI 1730280512
$7,143.94
in general payments reported to CMS, 2019-2025
49 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $581 · 2021: $1,141 · 2022: $1,148 · 2023: $927 · 2024: $1,335 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,780.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,376.77 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,032.79 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $475.35 | 2019-2025 | |
| Abbvie INC. | $455.45 | 2021-2025 | |
| Lilly USA, LLC | $314.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $262.39 | 2019-2022 | |
| Amgen INC. | $236.14 | 2021-2025 | Otezla, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $227.40 | 2022-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.27 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $176.07 | 2021-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $170.02 | 2023-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $163.47 | 2019-2023 | |
| Abbott Laboratories | $148.97 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $138.15 | 2021-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.90 | 2021-2025 | Jardiance |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ratchford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.